AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
SOURCE: Proceedings of the National Academy of Sciences, December 15, 1991;88(24):11241-11245.
Stable, replication-competent HIV-1 mutants resistant to the nonnucleoside HIV reverse transcriptase (RT) inhibitor nevirapine (BI-RG-587) emerge in cell cultures treated with the drug.
Nevirapine, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-o ne, is currently in Phase I/II clinical trials as an antiretroviral agent. The results of the current study, not unexpected in light of the mutability of HIV, suggest that nevirapine-resistant strains of HIV will arise in patients treated with the drug. However, since the mutations that …